Last updated: May 30, 2026
COREG is a branded carvedilol product. Supply for carvedilol tablets generally comes from multiple API producers and contract manufacturers that make and package generic-equivalent carvedilol strengths, since the active ingredient is not drug-product unique. The practical “supplier” map is therefore driven by: (1) carvedilol API sources, (2) tablet/compression-capability CDMOs, (3) packaging line availability for US-labeled NDCs, and (4) any licensor-brand requirements tied to brand Co-registry inventory and labeling.
Which companies supply carvedilol API used to make COREG tablets?
Carvedilol API is supplied by established small-molecule API manufacturers that export into the US and global CDMO ecosystem. COREG tablet supply depends on which API supplier is qualified for a given finished-dose manufacturer and NDC.
What are the common API supplier categories for carvedilol?
- Generic API manufacturers selling carvedilol monohydrate/active carvedilol to US-facing CDMOs and finished-dose plants.
- US- and EU-based API producers that maintain DMF-linked filings supporting downstream tablet compression and coating.
- Multi-site API networks where carvedilol bulk is produced under different regulatory regimes and then transferred into a particular tablet-manufacturing site’s quality system.
How do API qualifications affect COREG continuity of supply?
Carvedilol tablets require:
- consistent polymorph/solvate control (where applicable for the specific API grade),
- impurity profile control,
- supplier change approvals at the finished-dose level, and
- stability data aligned to the specific tablet strength and packaging.
Those constraints narrow the set of “supplier” candidates at the finished-dose stage even when API is widely available commercially.
Who manufactures COREG finished tablets and bottles, and what are the typical CDMO roles?
For branded COREG inventory, finished-dose manufacturing typically sits with established pharmaceutical plants capable of:
- wet or dry granulation,
- direct compression or tablet pressing (strength-dependent),
- film coating (for taste/appearance control),
- blistering or bottle filling,
- and serialization and packaging line compliance for US distribution.
Which finished-dose activities are usually sourced separately?
- API to tablet conversion (granulation/compression/coating)
- Primary packaging (blisters or bottles)
- Secondary packaging (cartons, labeling, inserts)
- Distribution logistics (warehousing and returns handling)
The “supplier list” for customers buying COREG inventory often includes both the finished-dose manufacturer and the packaging/fulfillment party.
What COREG formulations change the supplier and manufacturing requirements?
COREG is marketed in multiple strengths (tablet strengths vary by label), and formulation differences affect which manufacturing lines and excipient lots are acceptable.
Do COREG immediate-release strengths require different supplier setups?
Yes. Even when the API is the same (carvedilol), different tablet strengths can require:
- different compression force and tooling,
- different binder/disintegrant blends,
- different coating weight specs,
- and different blister/bottle configurations.
That drives differences in qualified component vendors and packaging suppliers per NDC.
Is COREG still protected by exclusivity or patents that affect who can supply?
Carvedilol is a mature generic small molecule. COREG “supplier” access is less constrained by exclusivity and more constrained by:
- FDA regulatory status of specific NDCs,
- ANDA product approvals linked to manufacturing sites,
- and historic brand supply chain qualification.
For procurement and sourcing decisions, the key gating factor is typically whether a given supplier can support the exact label NDC and packaging configuration required.
How does generic competition affect the COREG supplier market?
As carvedilol tablets face generic competition, the sourcing ecosystem widens:
- more API options per finished-dose plant,
- more qualified tablet manufacturers with overlapping capabilities,
- and more packaging vendors that support bottle/blister fill-finish.
In practice, brand inventory (or brand-labeled product) may be supplied through one or a few branded supply chains, while “carvedilol tablet supply” overall is highly multi-sourced.
What manufacturing quality and regulatory controls matter most for COREG sourcing?
Key diligence points when evaluating carvedilol tablet suppliers:
- GMP compliance history for the specific tablet strength and packaging configuration
- DMF/ASMF linkage for carvedilol API used at the finished-dose site
- validated cleaning and cross-contamination controls
- stability and re-test intervals consistent with shelf life
- packaging material vendor qualification and traceability
What are the main barriers to swapping COREG suppliers?
- API change control: impurity profile equivalence and stability alignment
- Tablet performance specs: dissolution and content uniformity
- Packaging lock-in: equipment qualification, label art control, and NDC-level validation
- Regulatory updates: site transfers and manufacturing change filings
Supplier comparison: how to map “who supplies” by NDC vs by capability
A practical way to build an actionable supplier list for COREG procurement is to split sourcing into two layers:
- NDC-linked supply chain
- finished-dose manufacturer site(s)
- packaging line(s)
- labeler-distributor
- Capability-linked supplier pool
- API producers qualified by CDMOs
- CDMOs with tablet compression/coating and packaging
- blister/bottle filling specialists
This separation explains why the broad carvedilol market has many suppliers, while a specific COREG NDC can show a narrower set of “real” supply sources.
Key Takeaways
- COREG “supplier” landscape is driven by carvedilol API producers and qualified tablet compression and packaging plants rather than by unique COREG-only IP.
- The decisive factor for COREG sourcing is the NDC-specific finished-dose and packaging supply chain.
- Swapping suppliers is gated by API-to-tablet equivalence (impurities, dissolution, stability) and packaging/NDC validation.
- Generic competition increases the number of capable plants, but NDC qualification keeps the effective supplier list tighter.
FAQs
-
How do I identify which plant makes a specific COREG NDC?
Match the NDC to the label/ANDA reference and the listing in FDA product labeling databases tied to manufacturing sites.
-
Can I source carvedilol API for COREG-like tablets from any vendor?
Only API vendors qualified into the finished-dose manufacturer’s quality system with regulator-acceptable change documentation.
-
Do COREG bottle and blister packaging suppliers differ?
They can, because primary packaging equipment, bottle/blister component qualification, and label layouts are NDC- and line-specific.
-
What change approvals are needed when switching carvedilol API suppliers?
Typically comparability work and regulatory reporting at the finished-dose level, including impurity control and stability alignment.
-
Are there CDMOs specializing in tablet coating and packaging for small molecules like carvedilol?
Yes; tablet coating and fill-finish for US labeling are common CDMO offerings, with selection driven by the specific strength formats and NDC packaging requirements.
References
No sources cited.
